TABLE 2.

Treatment‐related adverse events

	PEG monotherapy (N = 24)		PEG+pazopanib (N = 4)		PEG+anti‐PD‐1 (N = 38)
n, (%)	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Patients with ≥1 TRAE	22 (92)	14 (58)	4 (100)	4 (100)	37 (97)	26 (68)
Anemia	15 (63)	9 (38)	0	0	25 (66)	12 (32)
Thrombocytopenia	9 (38)	2 (8)	0	0	18 (47)	8 (21)
Neutropenia	0	0	0	0	3 (8)	3 (8)
Pancreatitis	0	0	1 (25)	1 (25)	0	0
Fatigue	10 (42)	2 (8)	4 (100)	0	15 (40)	1 (3)
Platelet count decreased	1 (4)	1 (4)	1 (25)	1 (25)	14 (37)	3 (8)
Aspartate aminotransferase increased	2 (8)	2 (8)	1 (25)	1 (25)	9 (24)	2 (5)
Alanine aminotransferase increased	2 (8)	2 (8)	1 (25)	1 (25)	6 (16)	1 (3)
Lipase increased	1 (4)	0	1 (25)	1 (25)	5 (13)	2 (5)
Blood alkaline phosphatase increased	1 (4)	1 (4)	1 (25)	1 (25)	2 (5)	0
Amylase increased	1 (4)	0	0	0	3 (8)	3 (8)
Hypertriglyceridemia	7 (29)	3 (13)	0	0	14 (37)	6 (16)
Pruritus	3 (13)	0	0	0	11 (29)	2 (5)

Note: The treatment‐related adverse events displayed in the table included only those with an incidence of ≥5% Grade 3/4/5.

Abbreviations: n, number of patients in group; PEG, pegilodecakin; TRAE, treatment‐related adverse event.